DigestRedComo funciona
Red
/
Empresas
Ev
No verificado

Evaxion

Sobre qué escribimos

Anuncios brevesBiotecnologíaFinanzasGestión empresarial/Administración de EmpresasPublicidad/Marketing/Medios de comunicación/Comunicación

42 Comunicados de prensa

Ver todos los comunicados de prensa
17/07/2026
Biotecnología
Anuncios breves
Evaxion to present three-year clinical efficacy data for personalized cancer vaccine EVX-01 at the ESMO Congress 2026
Fuente
Evaxion
Editor
GLOBENEWSWIRE
1.00
0
12/07/2026
Biotecnología
Anuncios breves
Evaxion presents new preclinical data for cytomegalovirus vaccine program EVX-V1
Fuente
Evaxion
Editor
GLOBENEWSWIRE
1.00
0
01/07/2026
Biotecnología
Anuncios breves
Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop
Fuente
Evaxion
Editor
GLOBENEWSWIRE
1.00
0
12/06/2026
Biotecnología
Anuncios breves
Evaxion receives Prix Galien UK Award for Best digital health solution
Fuente
Evaxion
Editor
GLOBENEWSWIRE
1.00
0
10/06/2026
Biotecnología
Anuncios breves
Evaxion presents new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia
Fuente
Evaxion
Editor
GLOBENEWSWIRE
1.00
0
12/05/2026
Biotecnología
Anuncios breves
Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress
Fuente
Evaxion
Editor
GLOBENEWSWIRE
1.00
0
07/05/2026
Biotecnología
Anuncios breves
Gestión empresarial/Administración de Empresas
Evaxion announces business update and first quarter 2026 financial results
Fuente
Evaxion
Editor
GLOBENEWSWIRE
1.00
0
04/05/2026
Biotecnología
Anuncios breves
Gestión empresarial/Administración de Empresas
Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026
Fuente
Evaxion
Editor
GLOBENEWSWIRE
1.00
0
27/04/2026
Biotecnología
Anuncios breves
Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer
Fuente
Evaxion
Editor
GLOBENEWSWIRE
1.00
0
17/04/2026
Biotecnología
Anuncios breves
Evaxion’s AI-Immunology™ platform demonstrates 86% vaccine target precision in phase 2 personalized cancer vaccine trial
Fuente
Evaxion
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0